Asensus Surgical, Inc. (NYSEAMERICAN:ASXC – Get Rating) Director William N. Starling, Jr. sold 27,010 shares of the business’s stock in a transaction on Monday, June 13th. The stock was sold at an average price of $0.40, for a total transaction of $10,804.00. Following the sale, the director now owns 13,846 shares in the company, valued at $5,538.40. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
Shares of NYSEAMERICAN ASXC opened at $0.38 on Friday. Asensus Surgical, Inc. has a one year low of $0.35 and a one year high of $3.68.
Several hedge funds and other institutional investors have recently modified their holdings of ASXC. GSA Capital Partners LLP acquired a new position in shares of Asensus Surgical during the 1st quarter worth $138,000. Goldman Sachs Group Inc. raised its stake in shares of Asensus Surgical by 68.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 210,737 shares of the company’s stock worth $133,000 after buying an additional 85,487 shares during the last quarter. Ergoteles LLC acquired a new position in shares of Asensus Surgical during the 1st quarter worth $36,000. Advisor Group Holdings Inc. raised its stake in shares of Asensus Surgical by 12.3% during the 1st quarter. Advisor Group Holdings Inc. now owns 279,923 shares of the company’s stock worth $2,090,000 after buying an additional 30,676 shares during the last quarter. Finally, Daiwa Securities Group Inc. raised its stake in shares of Asensus Surgical by 45.7% during the 1st quarter. Daiwa Securities Group Inc. now owns 95,198 shares of the company’s stock worth $60,000 after buying an additional 29,880 shares during the last quarter.
Asensus Surgical, Inc, a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, and Asia. It digitizes the interface between the surgeon and the patient to pioneer a new era of Performance-Guided surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery.
- Get a free copy of the StockNews.com research report on Asensus Surgical (ASXC)
- Vuzix Stock Stays Optimistic
- Palo Alto Networks: Pioneering AI in Cybersecurity
- Dividend Stocks and Your Roth IRA
- The Analysts Upgrade… Retail Stocks?
- The Q2 Earnings Season Could Be A Bloodbath
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Asensus Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asensus Surgical and related companies with MarketBeat.com's FREE daily email newsletter.